The effects of endopeptidase 24.11 inhibition on angiotensin-induced changes in plasma angiotensin II, aldosterone, and atrial natriuretic factor concentrations and blood pressure were assessed in normal volunteers. Two groups, each consisting of eight normal volunteers, received stepwise infusions of angiotensin II (2, 4, and 8 ng/kg per minute) on day 5 of dose administration with 25 mg every 12 hours (group 1) or 100 mg every 12 hours (group 2) of an oral inhibitor of endopeptidase 24.11 (UK 79300, candoxatril) or placebo in balanced randomized, double-blind, placebo-controlled crossover studies. Both doses of candoxatril significantly enhanced achieved plasma angiotensin II concentrations during infusions (group 1, p<0.001; group 2, p<0.01; overall treatment effect for combined data, p<0.001). This effect was most pronounced at the highest dose of angiotensin II (treatment-time interaction, p<0.0001 for combined data) and tended to be more marked with the higher dose of candoxatril (treatment-group interaction, p=0.08). The pressor response to angiotensin II was clearly enhanced by the lower dose of candoxatril; peak systolic and diastolic pressures exceeded placebo values by approximately 10 mm Hg (p<0.001 and p<0.05 for systolic and diastolic pressures, respectively). This effect of candoxatril was absent in group 2, which (unlike group 1) had exhibited a modest natriuretic response (sustained cumulative negative sodium balance, -70±21 mmol; p<0.01) to the higher dose of inhibitor. Baseline plasma aldosterone concentrations and the incremental aldosterone response to angiotensin II infusions were not significantly altered by low-dose (group 1) candoxatril. Basal aldosterone levels were slightly enhanced by the higher dose of inhibitor (p<0.05), but the incremental response to angiotensin II infusions was unchanged. Pretreatment with candoxatril caused plasma atrial natriuretic factor to rise above baseline values during angiotensin infusions (p<0.001, combined data). Inhibition of endopeptidase 24.11 significantly reduced clearance of infused angiotensin II in association with an enhanced pressor response to exogenous angiotensin when the inhibitor was given in doses below natriuresis. For cases in which a sufficient inhibitor was administered to elicit natriuresis, pressor responses did not change despite augmented plasma angiotensin II. These data carry implications for the potential therapeutic use of endopeptidase inhibitors in high and low renin states. (Circulation Research 1992;71:1501-1507 
I nhibition of endopeptidase EC 3.4.24.11 (endopeptidase 24.11) may be of therapeutic value in hypertension and heart failure.'-4 Endopeptidase 24.11 appears to play a central role in the initial degradation of atrial natriuretic factor (ANF).5-7 Endopeptidase 24.11 inhibitors have been shown to enhance plasma ANF and induce ANF-like end-organ effects in animals as well as both normal volunteers and patients with hypertension and heart failure.2-4,8 ANF exerts beneficial hemodynamic effects in hypertension and heart failure,9'10 but data have been limited because of the peptide's short half-life and the necessity for parenteral administration. Therefore, orally active endopeptidase 24 .11 inhibitors may offer a method for testing the effects of chronic enhancement of ANF bioactivity in cardiovascular disease.
However, ANF is not the sole vasoactive substrate for endopeptidase 24 Baseline and intrainfusion values of plasma Ang II and aldosterone concentrations are listed in Table 1 and/or illustrated in Figure 1 . Basal levels of angiotensin and aldosterone were unchanged by the lower dose (group 1) of candoxatril. Group 2 showed a trend toward higher basal levels of angiotensin ( Figure 1 and Table 1 , p=NS) and a significant increase in basal plasma aldosterone concentrations (p<0.05), which was consistent with the modest sodium depletion induced by the higher dose of candoxatril. Measured infusate concentrations of Ang II were similar for both candoxatril and placebo phases of the studies for both groups (1,119+41 and 1,139±35 ng/ml for candoxatril and placebo phases, respectively, in group 1; 985 +45 and 1,013+36 ng/ml for candoxatril and placebo phases, respectively, in group 2; p=NS for all comparisons of candoxatril versus placebo and group 1 versus group 2).
Candoxatril clearly enhanced achieved plasma Ang II concentrations particularly at higher angiotensin infusion rates ( Figure 1 ). This effect tended to be more pronounced in group 2. Ang II in group 1 and for all three doses of Ang II in group 2. HPLC analysis followed by radioimmunoassay (Dr. Mark Chappell, Cleveland Clinic Foundation, Cleveland, Ohio)18 revealed similar chromatographic profiles of Ang II and metabolites (Ang [3] [4] [5] [6] [7] [8] and Ang [2] [3] [4] [5] [6] [7] [8] ) in samples taken during infusions with and without candoxatril pretreatment. The ratio of octapeptide to metabolites was similar in both study phases, with increased immunoreactivity present for all moieties in the active phase. Therefore, levels of authentic Ang II were clearly enhanced by candoxatril.
Plasma aldosterone concentrations showed the expected dose-related increases during the stepwise Ang II infusions (Figure 1 ). In group 2, plasma aldosterone values were modestly but significantly increased by candoxatril before and during angiotensin infusions ( Figure 1, p<0 .05). However, in both groups the incremental response of plasma aldosterone to successive doses of Ang II was not altered by candoxatril despite the higher achieved plasma Ang II values (Figure 1) .
The pressor response to Ang II was clearly enhanced by the lower dose of candoxatril (group 1, Figure 2 with and without candoxatril pretreatment were absent in group 1 but statisti-1100 1200 1300 cally significant in group 2 (p<0.01). Time (h) sured peptide retains bioactivity and is therefore likely to be intact Ang II. The mechanisms whereby candoxatril impairs metabolic clearance of Ang II cannot be definitively stated from our current data. However, because endopeptidase 24.11 cleaves Ang II at the Tyr-Ile bond in vitro,"1 it seems probable that the inhibitor impedes Ang II degradation by tissue endopeptidases, at least when plasma Ang II is acutely increased threefold to fivefold.
In contrast to group 1, enhanced Ang II levels during infusions in group 2 subjects were not associated with an enhanced pressor response. Although the reason for this difference is unclear from our studies, several factors could contribute to this phenomenon. First, unlike group 1, subjects in group 2 who received the higher dose of candoxatril were mildly sodium depleted (relative to placebo status) -circumstances that are known to reduce the pressor response to Ang II.20,21 Second, in group 2 the diurnal endogenous Ang II levels during dose administration with candoxatril tended to be higher than control levels,'9 whereas in group 1 subjects values were closely matched in active and placebo phases. Such a trend to higher plasma and/or tissue Ang II in group 2 (if sustained) may downregulate vascular Ang II receptors and diminish the pressor response to infusions given after 5 days of candoxatril treatment. Third, with higher doses of candoxatril, enhancement of tissue and plasma (Figure 3 ) ANF may counteract the pressor action of Ang II, e.g., by reducing plasma volume22 and/or partially opposing the action of Ang II on vascular smooth muscle cells.
Despite augmented Ang II levels at high Ang II infusion rates, the plasma aldosterone incremental response was unaffected by candoxatril pretreatment in both groups. Furthermore, group 2 subjects with mild sodium depletion, which is known to increase glomerulosa sensitivity to Ang 11, 20 showed a similar Ang II/aldosterone dose-response relation. Because even small increments in plasma ANF may reduce aldoste-rone secretion in normal23 and hypertensive24 men, it is possible that enhanced plasma ANF levels before and/or during Ang II administration in candoxatriltreated subjects (Figure 3) The renin-angiotensin-aldosterone system is also activated in patients with deteriorating heart failure and animal models of heart failure.29 31 Many of the adverse manifestations of heart failure seem secondary to raised RAAS activity and are ameliorated by converting enzyme inhibition.31-33 Candoxatril has caused beneficial hemodynamic effects when given to heart failure patients in acute single-dose studies. 3 However, the more long-term effects of endopeptidase 24 .11 inhibition on RAAS activity in heart failure remain undetermined. It may be necessary to coadminister converting enzyme inhibitors or Ang II antagonists to gain optimum benefit from the use of endopeptidase inhibition in heart failure and hypertension.
The current data are derived from contrived circumstances in which plasma Ang II concentrations were rapidly elevated from normal to pathophysiological levels, and it remains to be confirmed that endopeptidase 24 .11 inhibition will continue to significantly delay metabolic clearance of Ang II in the medium or longer term with more gradual or subtle elevation of endogenous angiotensin II, and, if so, whether such an action would be sufficient to exert significant hemodynamic effects. However, the potential importance of the observed interaction indicates that carefully controlled trials (of a range of endopeptidase inhibitors) that incorporate monitoring of both clinical status and neurohumoral status will be required to establish the appropriate role, if any, of endopeptidase 24.11 inhibitors in the management of cardiovascular disease.
